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Early postoperative mortality after simultaneous
or staged bilateral primary total hip arthroplasty:
an observational register study from the swedish
Hip arthroplasty register
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Abstract
Background: Approximately a fifth of all total hip arthroplasty (THA) patients suffers from bilateral osteoarthritis of
the hip. It is unclear whether mortality risks differ between simultaneous bilateral THA and staged bilateral THA. We
investigated mortality after simultaneous THA compared with staged bilateral THA in the largest cohort hitherto
reported.
Methods: The 42,238 patients reported to have received bilateral primary THA from 1992 to 2012 in the Swedish
Hip Arthroplasty Register were included. Tumours and fractures as underlying diagnoses were excluded. The time
interval between the first and second THA was divided into four categories or treated as a continuous variable.
Unadjusted survival was calculated according to Kaplan-Meier and adjusted Cox regression models were fitted in
order to calculate crude and adjusted hazard ratios (HR) for the risk of death within different time frames.
Results: Patients selected for simultaneous bilateral surgery were younger, more often male, and had lower ASA
(American Society of Anesthesiologists) class than patients receiving staged procedures. The adjusted 90-day mortality
after the second procedure did not differ between the four investigated groups (simultaneous bilateral [HR 1.3,
CI 0.5-3.3], surgeries within 6 months [HR 1.1, CI 0.6-2.0], surgeries between 7 and 12 months [HR 0.7, CI 0.4-1.2],
with second surgery after >12 months as the reference group). For patients older than 75 years, men, patients with
ASA class 3 or above, and for patients with rheumatoid arthritis (RA) the 90-day mortality was increased. The unadjusted
risk of implant revision of any hip was slightly higher for patients with simultaneous bilateral THA compared to those
with staged procedure within one year, but after adjustment for age, gender, diagnosis and implant fixation these
differences were no longer statistically significant.
Conclusion: There were no clinically relevant differences in early postoperative mortality between simultaneous and
staged bilateral surgery in healthy patients. Advanced age, RA, a high ASA class and male sex increased the risk of
death within 90 days. There may be an issue with enhanced risk of implant revision in patients with simultaneous
bilateral THA that needs to be explored further.
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Background
A substantial proportion of patients receiving a primary
total hip arthroplasty (THA) suffers from bilateral osteo-
arthritis (OA) of the hip, and in Sweden approximately
17% of THA patients have symptoms motivating inser-
tion of a contralateral THA at some point [1]. Bilateral
disease may already be manifest when patients undergo
their first THA, and in such cases either simultaneous
or staged bilateral surgery can be performed.
THA is considered a safe procedure. The early postop-
erative mortality is low and has decreased over the last
years, and a systematic review concluded that the aver-
age 90-day mortality after THA was 0.7% [2,3]. Simul-
taneous bilateral surgery is also described as feasible and
safe. Excellent functional results after simultaneous bilat-
eral surgery were already reported by Jaffe and Charnley
in 1971 [4] and early postoperative mortality after this
procedure is reported to be low. 90-day mortalities
between 0.14 and 0.16% [5,6] and a peri-operative mor-
tality (without specification of the exact time frame) of
0.31% vs. 0.18% when compared with unilateral surgery
[7] are reported. Putative benefits of simultaneous bilat-
eral THA include a single hospital stay, a shorter
rehabilitation period, higher patient satisfaction, and
lower costs per patient [8].
There remain however concerns about the safety of
simultaneous bilateral THA procedures: A higher amount
of haemorrhage, an increased number of thromboembolic
events and cardiopulmonary complications, and reduced
range of motion have been described after simultaneous
bilateral operations [9-11].
A large number of patients is needed in order to
address the issue of early postoperative mortality and
morbidity. Assuming that 90-day mortality is 0.7% after
THA [3], 1,346 patients with simultaneous bilateral
THA and 13,460 controls would be required in order to
detect an increase in mortality by a factor of 2 (alpha =
0.05, power = 80%; [12,13]). Given these numbers, many
of the cited studies seem underpowered to detect clinic-
ally relevant differences in early postoperative mortality,
since the reported study populations range from 35 to
6,258 [6,7,14-17] with the exception of one register study
from New Zealand [18]. In addition, mortality after
simultaneous bilateral THA has most commonly been
investigated using unilateral surgery for comparison, and
not staged bilateral surgery, which would be the relevant
control group [6,7,16]. Thus, there is a lack of know-
ledge about the early postoperative mortality after simul-
taneous bilateral THA compared with staged bilateral
procedures in larger cohorts.
The Swedish Hip Arthroplasty Register (SHAR) with
nationwide individualised information on THA surgery
combined with dates of death for deceased patients is a
suitable platform to investigate the safety of simultaneous
bilateral THA. We evaluated if there is an increased risk
of early mortality after this procedure compared with
staged bilateral THA.
Methods
Source of data
Data was obtained from the SHAR database. THA per-
formed in Sweden have been reported to this register
since 1979, initially as aggregated data based on hospital
units and since 1992 as individualized data based on per-
sonal identification numbers. In Sweden all citizens have
a personal identification number that is used in every
contact with healthcare providers. Since the investigated
endpoint was postoperative mortality the analyses take
their starting point in 1992. The SHAR has been repeat-
edly validated and on national level the completeness of
registrations has been stable around 96-98% [1,19,20] al-
though some studies have reported lower completeness
for the endpoint revision surgery [1,21]. Registration of
height and weight to calculate Body Mass Index (BMI)
and American Society of Anesthesiologists (ASA) class
were included in the SHAR from 2008. The complete-
ness with respect to these parameters has improved over
the years and in 2012 it reached 94.7% for BMI and
97.5% for ASA class [1].
Patient-reported outcomes data were not included in
the analysis. Neither socioeconomic factors nor comor-
bidities are registered in the SHAR and were therefore
not investigated.
The Regional Ethical Review Board in Gothenburg
(2013: 360–13) approved our study. All participants have
received written information about the SHAR and given
the choice not to participate in the registry or associated
research. Written informed consent for participation has
not been obtained. This is in consistency with the Swedish
Patient Data Law from 2009.
Study population
During the study period (1992–2012) 42,238 THA had
been performed as bilateral THA and thus 42,238
patients (22.1% of all patients registered during the study
period) with bilateral THA were included in our ana-
lyses. In this study population 25,115 (59.5%) were
women. The most common underlying diagnosis was
OA (n = 38,779, 92%), the most common age group was
60–75 years (n = 23,436, 55.5%), and the most common
fixation method during the second procedure was
cemented (n = 33,836, 80.4%; Table 1). The age grouping
is the same as that is used in the annual reports from
the SHAR. Since information on BMI and ASA was not
included in the SHAR until 2008 a subcohort of 15,226
patients included from 2008 and onwards was evaluated
in a separate analysis (Table 2). Patients with femoral
neck fractures and insertion of THA due to primary or
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metastatic malignancy were excluded from the study
population. Revision arthroplasties were also not included
in the analyses.
For comparative reasons patients who had had a uni-
lateral THA during the same time period (1992–2012)
were also analysed. This cohort consisted of 148,718 pa-
tients (87.9% of all patients registered during the study
period). In the unilaterally operated population 85,102
(57.2%) were women. The most common underlying
diagnosis was OA (n = 131,405; 89.3%), the most common
age group was 60–75 years (n = 76,473; 51.4%), and the
most common fixation method during the THA proced-
ure was cemented (n = 121,393; 81.6%).
Terminology
The term “simultaneous THA” is commonly used for
one-stage surgery although the hips are commonly
operated upon sequentially but during one anaesthesia.
This definition of simultaneous is used in our study. The
most common diagnoses in our study population were
primary OA and inflammatory arthritis (RA; rheumatoid
arthritis and related inflammatory joint diseases) (Table 1).
Other diagnoses such as childhood hip disease, femoral
head necrosis and secondary arthritis were more rare and
were therefore grouped together as “other”.
Most commonly both the cup and stem were cemen-
ted followed by fixation without cement. Hybrid fixation
modes including one cemented and one uncemented
component (hybrids, reversed hybrids, resurfacings) were
less frequently used and therefore classified into one
group (“other”, Table 1). ASA classes 1 and 2 were most
common, ASA class 3 was less common, and class 4 and 5
was highly infrequent, why the latter 3 categories were
grouped together as ASA score 3–5. Age, fixation method,
Table 1 Demographics for the 42,238 individuals with bilateral THA operated 1992-2012
Op same day (n = 1,680) Op ≤ 6 months (n = 4, 867) Op 7–12 months (n = 7,809) Op > 12 months (n = 27, 882) p-value
n % n % n % n %
Age
<50 308 18.3 357 7.3 454 5.8 831 3.0 <0.001a
50-59 424 25.2 823 19.0 1,278 16.4 3,052 10.9
60-75 788 46.9 2,792 57.4 4,499 57.6 15,357 55.1
>75 160 9.5 795 16.3 1,578 20.2 8,642 31.0
Diagnoses
OA 1,346 80.4 4,309 88.8 7,112 91.4 26,012 93.4 <0.001a
RA 193 11.5 279 5.7 316 4.1 1,033 3.7
Otherb 136 8.1 266 5.5 351 4.5 819 2.9
Sex
Male 767 45.7 2,074 42.6 3,176 40.7 11,106 39.8 <0.001a
Female 913 54.3 2,793 57.4 4,633 59.3 16,776 60.2
Fixation
Cemented 931 55.8 3.697 76.5 6,224 80.1 22,984 82.6 <0.001a
Uncemented 372 22.3 563 11.6 686 8.8 2,147 7.7
Otherc 364 21.8 575 11.9 856 11.0 2,683 9.6
aChi - square.
bSequelae from childhood hip disease, femoral head necrosis, secondary OA.
cHybrid, reversed hybrid, and resurfacing.
All data in this table concerns the second operation.
Table 2 The subcohort of 15,226 individuals with information on ASA class and BMI
Op same day (n = 450) Op < 6 months (n = 1,598) Op 6–12 months (n = 2,286) Op > 12 months (n = 10,892) p-value
BMI X (SD) 26.9(4.7) 27.3(5.7) 27.5(4.8) 27.5(5.0) 0.050a
ASA n (%)
1 157(33.5%) 472(29.1%) 624(26.5%) 2,304(20.8%) <0.001b
2 250(53.3%) 974(60.1%) 1,398(59.4%) 6,823(61.5%)
3-5 62(13.2%) 174(10.7%) 331(14.1%) 1,967(17.7%)
aANOVA.
bChi-square.
15,226 individuals with ASA and BMI registered. 15,536 had ASA, and 15,226 had BMI registered.
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BMI, and ASA class were measured at the time of the sec-
ond operation.
The time interval between the first and second THA
was either treated as a continuous variable or divided
into four categories (simultaneous bilateral surgery, ≤
6 months [1–179 days], 7–12 months [180–365 days],
and >12 months [>365 days] between surgeries).
We investigated 30-day-, 90-day-, 10-year- and overall
mortality after the second surgery (index surgery). Our
primary endpoint was 90-day mortality since this param-
eter captures both perioperative deaths, early postopera-
tive and delayed postoperative deaths such as those
caused by thromboembolic events [5,6]. 30-day-, 10-year-
and overall mortality after the second surgery were sec-
ondary endpoints. Revision surgery of any hip after the
second THA surgery was also explored as an additional
endpoint.
Statistics
We adhered to the guidelines on statistical analyses of
register data [22,23]. Follow-up started on the day of the
second surgery and ended on the day of death, emigra-
tion, or December 31st 2012, whichever came first. Con-
tinuous data were described using means, medians, and
ranges, and 95% confidence intervals (CI) were used to
describe estimation uncertainty. Categorical data were
summarized in cross-tables and the Chi-square test or
Fisher’s exact test were used to investigate differences
between groups. Kaplan-Meier survival analysis was per-
formed to calculate unadjusted survival for different
time periods (see above). Cox regression models were
fitted for each covariate at a time in order to calculate
crude hazard ratios (HR) with CI, and covariates were
subsequently included in multiple regression models
in order to calculate adjusted HR with CI. The choice
of covariates included in multiple regression models
was based upon assessment of relevance and non-
interference using directed acyclic graphs as previ-
ously suggested [24]. For exploratory analyses the
material was stratified into different periods of time
(1992–1996, 1997–2001, 2002–2006, 2007–2011 and
2012). The resulting five subcohorts were analysed
separately as above. Separate models were also fitted for a
subcohort of patients where information on BMI and ASA
was available. Model assumptions were investigated by cal-
culating and plotting the correlation coefficient between
transformed survival time and the scaled Schoenfeld resid-
uals. The level of significance was set at p < 0.05. The R
software (package 3.0.2 [25]) and SPSS (version 22) were
used for analyses.
Results
63 patients (0.1%) died within 30 days after second sur-
gery, 125 (0.3%) within 90 days and 6,178 (14.7%) within
10 years. Crude survival for the investigated groups is
given in Table 3. The group of patients that underwent
simultaneous bilateral surgery differed from the other
groups with respect to prevailing diagnoses, type of
fixation, and age. OA was the dominant underlying
diagnosis (80.4%) but RA was more common among
patients operated with simultaneous bilateral surgery
than among those that underwent staged procedures.
Patients selected for simultaneous bilateral surgery
were younger and slightly more often males. Alterna-
tives to cemented fixation were chosen more often in
this group (See Table 1).
Early postoperative mortality
Unadjusted survival at different time points is given for
the four investigated groups in Table 3 and unadjusted
90-day survival is depicted in Figure 1. For comparison,
the unadjusted survival in the unilaterally operated con-
trol cohort was 99.4% (CI 99.3-99.4) 90 days after the
index THA surgery.
For bilaterally operated patients, the risk of dying
within 90 days after the second procedure was not dif-
ferent between the four investigated groups after adjust-
ment for sex, age, diagnosis, and type of prosthesis
fixation (Table 4). When time between surgeries was
treated as a continuous variable the timing of surgery
still had no influence on the adjusted risk of dying
within 90 days (HR 1.0, CI 1.0-1.0). However, for pa-
tients over 75 years old and for men, the risk of dying
within 90 days was increased (Table 4) and there was a
doubled risk of dying within 90 days after index surgery
for patients with RA (HR 2.3, CI 1.1-4.7). Analyses of
the subcohort of patients among whom information on
ASA class and BMI was available indicated that ASA
class 3 and above was a risk factor for increased 90-day
mortality after index surgery when compared with ASA
class 1 (HR 8.2, CI 1.8-37.3, after adjustment for sex, type
of prosthesis fixation, and BMI, see Table 5). Adding
underlying diagnoses to the adjusted model (adjustment
for sex, type of prosthesis fixation, and BMI) did not alter
the 90-day mortality estimates for the subcohort with in-
formation on ASA class and BMI (data not shown).
After adjustment for sex, age, diagnosis, and type of
prosthesis fixation the HR for the risk of dying within
the first 30 postoperative days after the second pro-
cedure was 2.0 (CI 0.6-6.6) for simultaneous surgery,
1.4 (CI 0.7-3.0) for surgery within 6 months, and 0.7
(CI 0.3-21.5) for surgery between 7 and 12 months
with second surgery after more than 12 months as the
reference group (Table 6).
Overall mortality
The crude and adjusted overall risk of death for the four
investigated groups (simultaneous, ≤ 6 months, 7–12
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months and > 12 months) differed significantly be-
tween groups, with 10-year and overall mortality being
lower in the groups of patients selected for simultan-
eous bilateral surgeries or surgeries within 1 year. The
adjusted HR for the overall risk of death was 0.9 (CI
0.8-1.0) for simultaneous surgery, 0.9 (CI 0.8-1.0) for
surgery within 6 months, and 0.9 (CI:0.9-1.0) for sur-
gery between 7 and 12 months after adjustment for
sex, age, diagnosis, and type of prosthesis fixation, and
with second surgery more than 12 months after the
first THA as the reference group (Table 7).
The overall 1-year mortality after the second THA
was 1.2% (1,200 per 100,000) for all patients grouped
together.
Revision surgery
Revision surgery of either hip after the second THA sur-
gery was slightly more common in simultaneously oper-
ated patients compared to the patients operated with a
staged procedure [4-7,14-16] 240 [7.1%], surgeries within
6 months n 495 [5.1%], surgeries between 7 and 12 months
n 828 [5.3%] and second surgery after >12 months n 3,573
[6.4%].
The unadjusted risk of revision for the simultan-
eously operated patients compared to the patients
operated with staged procedure was [4-7,14-16]. When
adjusting for sex, age, diagnosis and type of prosthesis
fixation this difference in the risk estimates disap-
peared [4-7,14-16].
Table 3 The four investigated groups and time intervals, with crude survival percentages and 95% confidence intervals
for each group
30 days 90 days 10 years
Survival CI (95%) Survival CI (95%) Survival CI (95%)
Time interval
Simultaneous 99.8 99.6-100.0 99.7 99.4-100.0 82.7 80.4-85.1
≤6 months 99.8 99.7-99.9 99.7 99.6-99.9 78.1 76.5-79.|7
7-12 months 99.9 99.8-100.0 99.8 99.7-99.9 76.9 7|5.7-78.2
>12 months 99.8 99.8-99.9 99.7 99.6-99.7 71.5 70.7-72.3
Figure 1 Early mortality up to 90–days after second THA in bilaterally operated patients. Unadjusted survival according to Kaplan–-Meier.
Shaded areas indicate 95% confidence intervals.
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Observation period as a covariate
We stratified the material into five subcohorts with
respect to the year of surgery. The mortality was some-
what lower for the more recently operated patients com-
pared to patients operated during earlier time periods
(90-day unadjusted overall survival 1992–1996 was
99.7% [CI 99.5-99.9], 1997–2001 99.5% [CI99.4-99.7],
2002–2006 99.7% [CI 99.6-99.8], 2007–2011 99.8% [CI
99.7-99.9] and 2012 99.8% [CI 99.6-99.9]). Apart from
that no relevant differences in mortality could be detected
in the stratified material compared to the results obtained
on the entire study population (data not shown).
Simultaneous surgery was more common early in the
study period. 227 patients (6.4%) were operated simul-
taneously 1992–1996, 373 patients (4.9%) in 1997–2001,
500 patients (4.2%) in 2002–2006, 494 patients (3.2%)
2007–2011 and 86 patients (2.5%) were operated simul-
taneously in 2012. The time period was introduced as a
covariate in a Cox regression model for 90-day mortality.
After adjustment for sex, age, diagnosis and type of
prosthesis fixation the risk of 90-day mortality was not
statistically significantly different during the investigated
time periods (1997–2001 [HR 1.3, CI 0.7-2.4], 2002–2006
[HR 0.8, CI 0.4-1.5], 2007–2011 [HR 0.5, CI 0.3-1.1], 2012
[HR 0.6, CI 0.2-1.5] with the first period 1992–1996 as
reference).
Exploratory analyses
Exploratory analyses showed that the type of hospital
where the procedures were performed and the type of
surgical approach did not influence the risk of death
within 30 or 90 days after the second procedure (data
not shown). Hybrids, reverse hybrids, and resurfacing
arthroplasties were also analysed as separate modes of
fixation instead of being grouped together, but this did
not influence parameter estimates in a statistically sig-
nificant manner (data not shown).
Instead of categorizing the time between surgeries into
four groups we also investigated the time interval between
the two THA procedures in each patient as a continuous
variable. This analysis indicated that elapsed time between
surgeries was not a statistically significant risk factor for
death within 90 days after the second THA.
Discussion
17% of patients receiving a primary THA in Sweden suf-
fer from or will develop bilateral disease with symptoms
Table 4 Hazard ratio for 90-day mortality
Crude Adjusted
HR CI (95%) p HR CI (95%) p
Time interval
Simultaneous 0.69 0.4-2.2 0.82 1.3 0.5-3.3 0.59
≤6 months 0.9 0.5-1.5 0.63 1.1 0.6-2.0 0.72
7-12 months 0.5 0.3-1.0 0.03 0.7 0.4-1.2 0.14
>12 months (ref)a 1.0 - - 1.0 - -
Sex
Male 1.0 - - 1.0 - -
Female 0.7 0.5-1.0 0.06 0.6 0.4-0.9 0.01
Age
<50 1.1 0.4-3.2 0.80 1.0 0.3-3.0 0.98
50-59 0.7 0.3-1.5 0.36 0.7 0.3-1.5 0.34
60-75 (ref) 1.0 - - 1.0 - -
>75 3.6 2.6-5.8 <0.001 3.8 2.6-5.6 <0.001
Fixation
Cemented (ref) 1.0 - - 1.0 - -
Uncemented 0.5 0.2-1.1 0.09 0.9 0.4-2.2 0.80
Otherb 0.7 0.4-1.3 0.27 1.1 0.6-2.2 0.75
Diagnoses
OA (ref) 1.0 - - 1.0 - -
RA 1.7 0.9-3.3 0.13 2.3 1.1-4.7 0.02
Otherc 0.4 0.1-1.7 0.24 0.6 0.1-2.4 0.44
Adjustment for sex, age, diagnosis, and type of prosthesis fixation.
aRef: reference.
bHybrid, reversed hybrid, and resurfacing.
cSequelae from childhood hip disease, idiopathic femoral head necrosis,
secondary OA.
Number of events 125.
Table 5 Hazard ratios for 90-day mortality for the ASA
class and BMI subcohort consisting of 15,226 individuals
Crude Adjusted
HR CI (95%) p HR CI (95%) p
Time interval
Simultaneous 1.0 0.1-7.1 0.97 1.4 0.2-10.6 0.75
≤6 months 0.5 0.1-2.3 0.41 0.7 0.2-2.9 0.61
7-12 months 0.8 0.3-2.2 0.61 0.9 0.3-2.5 0.78
>12 months (ref)a 1.0 - - 1.0 - -
BMI 1.0 0.9-1.1 0.83 1.0 0.9-1.1 0.76
ASA
1(ref) 1.0 - - 1.0 - -
2 2.3 0.7-7.7 0.19 3.0 0.7-13.0 0.15
3-5 6.6 1.9-22.9 0.003 8.2 1.8-37.3 0.006
Sex
Male 1.0 - - 1.0 - -
Female 0.8 0.4-1.5 0.45 0.4 0.4-1.5 0.40
Fixation
Cemented (ref) 1.0 - - 1.0 - -
Uncemented 0.4 0.1-1.6 0.18 0.5 0.1-2.0 0.30
Otherb 0.7 0.3-2.1 0.56 0.8 0.3-2.4 0.73
Adjustment for sex, ASA, BMI, and type of prosthesis fixation.
aRef: reference group.
bHybrid, reversed hybrid, and resurfacing.
Number of events 32.
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motivating insertion of a contralateral THA [1]. Some
are operated bilaterally on one day, which is considered
a safe procedure. However, doubts regarding postopera-
tive mortality remain since previous studies only in-
cluded small populations or lacked a relevant control
group [4-7,14-16].
In this observational study on the largest cohort hith-
erto reported we compare simultaneous bilateral THA
with staged bilateral surgery, which is a more adequate
reference group when compared to patients that only
underwent one THA. The results indicate that early
mortality after simultaneous bilateral surgery is not in-
creased when compared with staged procedures. We
also find that patients selected for simultaneous proce-
dures are younger and healthier than those that receive
staged surgery.
Postoperative mortality after THA
THA is a relatively safe procedure and early postopera-
tive mortality is low, varying between 0.1% to 0.7%
(30 day mortality 0.1% [26], 90 day mortality 0.29% [2]
and 0,7% [1]). In Sweden, the 90-day mortality after
THA, with unilateral and bilateral together, has been re-
ported to be 0.7%. The reason for this slightly increased
mortality in the Swedish population in comparison to
some other studies could be explained by the inclusion
of patients with femoral neck fractures in the Swedish
records. Differing patient demography or varying com-
pleteness of mortality records can also contribute to this
phenomenon [1]. However, in a systematic review on the
subject of mortality following THA Singh et al. [3]
describe a 90-day mortality of 0.7% which supports the
figures reported from the SHAR.
The 1-year mortality after the second THA was 1,2%
(1,200 per 100,000) for all patients together. This figure
can be compared with the overall Standardized Death
Rate (SDR) of the Swedish population that was 514 per
100,000 in 2010 [27], indicating a higher 1-year mortality
in THA patients when compared with the average popu-
lation. This finding is in agreement with the fact that
THA patients are older than the average population.
RA as the underlying diagnosis for THA surgery, male
gender, and an age above 75 years at the time of second
surgery were associated with an increased risk of death
within 90 days. These findings were expected. Due to their
comorbidities patients with RA represent a vulnerable
group, and earlier work indicates a higher complication
Table 7 Hazard ratio for overall mortality
Crude Adjusted
HR CI (95%) p HR CI (95%) p
Time interval
Simultaneous 0.6 0.5-0.6 <0.001 0.9 0.8-1.0 0.089
≤6 months 0.8 0.7-0.8 <0.001 0.9 0.9-1.0 0.0|32
7-12 months 0.8 0.8-0.8 <0.001 0.9 0.9-1.0 0.007
>12 months (ref)a 1.0 - - 1.0 - -
Sex
Male 1.0 - - 1.0 - -
Female 0.8 0.8-0.8 <0.001 0.2 0.1-0.2 <0.001
Age
<50 0.2| 0.2-0.3 <0.001 0.2 0.1-0.2 <0.001
50-59 0.3 0.3-0.4 <0.001 0.4 0.3-0.4 <0.001
60-75 (ref) 1.0 - - - - -
>75 3.1 3.0-3.3 <0.001 3.2 3.1-3.4 <0.001
Fixation
Cemented (ref) 1.0 - - - - -
Uncemented 0.3 0.2-0.3 <0.001 0.7 0.6-0.8 <0.001
Otherb 0.3 0.3-0.4 <0.001 0.7 0.6-0.7 <0.001
Diagnoses
OA (ref) 1.0 - - 1.0 - -
RA 1.2 1.1-1.3 <0.001 2.2 2.0-2.4 <0.001
Otherc 0.7 0.6-0.8 <0.001 1.5 1.3-1.7 <0.001
Adjustment for sex, age, diagnosis, and type of prosthesis fixation.
aRef: reference.
bHybrid, reversed hybrid and resurfacing.
cSequelae from childhood hip disease, idiopathic femoral head necrosis,
secondary OA.
Number of events 8267.
Table 6 Hazard ratio for 30-day mortality
Crude Adjusted
HR CI (95%) p HR CI (95%) p
Time interval
Simultaneous 1.1 0.3-3.6 0.86 2.0 0.6-6.6 0.26
≤6 months 1.0 0.5-2.2 0.96 1.4 0.7-3.0 0.39
7-12 months 0.6 0.3-1.2 0.15 0.7 0.3-1.5 0.37
>12 months (ref)a 1.0 - - 1.0 - -
Sex
Male 1.0 - - 1.0 - -
Female 0.8 0.5-1.3 0.38 0.7 0.4-1.2 0.16
Age
<50 0.5 0.1-4.1 0.55 0.6 0.1-5.3 0.68
50-59 0.4 0.1-1.6 0.18 0.4 0.1-1.7 0.22
60-75 (ref) 1.0 - - 1.0 - -
>75 3.6 2.1-6.1 <0.001 3.8 2.2-6.5 <0.001
Fixation
Cemented (ref) 1.0 - - 1.0 - -
Uncemented 0.5 0.1-1.5 0.21 1.0 0.3-3.6 0.97
Otherb 0.4 0.1-1.3 0.12 0.7 0.2-2.4 0.59
Adjustment for sex, age, and type of prosthesis fixation. Stratified for diagnosis
since proportional hazard was missing for this variable.
aRef: reference.
bHybrid, reversed hybrid and resurfacing.
Number of events 63.
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rate for RA patients although they are generally younger
at time of surgery and more often female [28-30].
The larger proportion of men among patients selected
for simultaneous bilateral surgery in our material is not-
able since our analyses and other studies indicate that
male sex is associated with an increased risk of early
postoperative death when compared with females
[26,31,32]. The reason why men are more often selected
for bilateral surgery is unclear. From a general perspec-
tive there are no reasons to believe that men are in a
greater need of pain-free hips. In the SHAR males are
operated at a younger age than females, which may sug-
gest an earlier debut of symptoms or a gender influence
on indications. Nonetheless, it might be that simultan-
eous bilateral THA surgery is underutilized in females.
Strengths and weaknesses of this study
Many of the cited studies seem underpowered to detect
clinically relevant differences in early postoperative
mortality given the numbers mentioned above [5-7]. In
addition, mortality after simultaneous bilateral THA is
commonly compared with mortality after unilateral sur-
gery [6,7,16] but only very rarely with mortality after
staged bilateral surgery (Saito S, Tokuhashi Y, Ishii T,
Mori S, Hosaka K and Taniguchi S [15]; study cohort of
n = 178 THA, Shih CH and Ho WB [14]; n = 70 THA,
Hooper GJ, Hooper NM, Rothwell AG and Hobbs T
[18]; study cohort n = 13,151 THA), which would be the
relevant control group. A strength of our study is the
relatively large size of the investigated cohort, giving the
opportunity to detect clinically relevant differences in
early mortality after THA.
In this study on the largest cohort hitherto reported
we compare simultaneous bilateral THA with staged bi-
lateral surgery. The time interval between the first and
second procedure in staged THA was divided into four
categories (simultaneous bilateral surgery, second surgery
within 6 months, between 7 to 12 months, and second
surgery after more than 12 months). Patients who
undergo 2 THA within 12 months can be considered
likely to have had bilateral OA when the decision regard-
ing the first surgery was made and might have been
offered a simultaneous procedure [33]. Patients who
undergo 2 THA with more than 12 months in between
can be considered less likely to have been eligible for a
simultaneous procedure when the decision regarding the
first surgery was made. These arbitrary categories can be
questioned, although they were chosen in line with previ-
ous work on this topic [33].
As in other observational studies the issue of selection
bias has to be considered. Patients selected for simultan-
eous bilateral surgery were younger, were more often
men, had lower ASA class, more often had other under-
lying diagnoses than OA, and were more often selected
for uncemented or other fixation methods. Thus, the in-
vestigated groups were not equal with respect to these
aspects. From a clinical point of view the most relevant
approach would be to compare patients with bilateral
symptoms and with the same type of hip disease who at
their first visit are judged to be subjected to either a sim-
ultaneous bilateral operation or a staged procedure. A
comparison of those operated simultaneously with those
operated within 6 or perhaps even 12 months would be
interesting. Patients planned for staged surgery may suf-
fer from complications postponing the planned second
stage or preventing the patient from having the second
operation. Some may even die before their second hip is
operated. In our study we calculated mortality after the
second procedure, consequently the postoperative mor-
tality was slightly underestimated because those who
died between the first and second operation were ex-
cluded. Theoretically one could estimate this excess
mortality rate, but we have refrained from doing so due
to the risk of including too many uncertainties. This is a
drawback of our study but nonetheless speaks in favour
of simultaneous bilateral procedure since the mortality
rate in the staged group is a more or less conservative
approximation.
The SHAR does not include information on medical
comorbidities, causes of death, and causes of readmis-
sion after THA surgery. Medical comorbidities influence
the clinical outcome after THA surgery [34] and could
affect peri- and postoperative mortality [2,30,35,36].
Ideally our analyses should have been adjusted for med-
ical comorbidity, and further studies based on combined
data from the SHAR and the national inpatient register
would therefore be of great value.
The question of selection bias has to be considered
also when analysing the revision rates of this study. We
found slightly increased revision rates in simultaneously
operated patients compared to patients who had had a
staged procedure. An observandum is that patients
selected for a simultaneous procedure more often were
selected for uncemented or other fixation methods com-
pared to patients selected for a staged procedure.
Conclusion
Our results based on register data on 42,238 patients
show no relevant difference in perioperative mortality
between simultaneous and staged bilateral surgery in
healthy patients with symptoms motivating this type of
procedure. Advanced age, RA, high ASA class and male
sex increased the risk of death, which should be taken
into consideration when making the choice between
simultaneous or staged bilateral THA.
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